American Capital Management Inc. Takes $4.49 Million Position in Insulet Corporation $PODD

Key Points

• American Capital Management initiated a $4.49 million position in Insulet during the second quarter by purchasing 29,455 shares. Several other institutional investors also increased their holdings.
• Insulet reported a strong second quarter, with adjusted EPS of $1.66 and revenue of $801.7 million, up 23.5% year over year and above analyst expectations. However, analysts remain concerned about sustaining growth following the company’s 2026 guidance reset.
• The stock faces significant risks from reported Omnipod recalls and related securities lawsuits alleging manufacturing, safety and compliance disclosure issues. Analyst sentiment is mixed, with a consensus “Hold” rating and average price target of $195.40 versus the shares’ opening price of $143.38.

American Capital Management Inc. bought a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 29,455 shares of the medical instruments supplier's stock, valued at approximately $4,485,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Glenmede Investment Management LP increased its stake in Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier's stock worth $708,000 after purchasing an additional 35 shares in the last quarter. Curi Capital LLC lifted its stake in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock worth $1,365,000 after acquiring an additional 36 shares in the last quarter. Great Lakes Advisors LLC boosted its position in Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier's stock worth $791,000 after acquiring an additional 40 shares during the period. Camarda Financial Advisors LLC increased its stake in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier's stock valued at $2,304,000 after buying an additional 40 shares during the period. Finally, Larson Financial Group LLC grew its stake in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 47 shares in the last quarter.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Insider Activity

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.36% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PODD. Benchmark dropped their price target on Insulet from $250.00 to $185.00 and set a "buy" rating for the company in a report on Thursday, August 6th. BTIG Research downgraded Insulet from a "buy" rating to a "neutral" rating in a report on Thursday, August 6th. Piper Sandler decreased their price objective on Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Bank of America dropped their price objective on Insulet from $288.00 to $208.00 and set a "buy" rating for the company in a report on Monday, May 18th. Finally, Evercore set a $180.00 target price on shares of Insulet in a report on Monday, July 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $195.40.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $143.38 on Thursday. The company's 50 day simple moving average is $154.52 and its 200 day simple moving average is $182.09. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The stock has a market capitalization of $9.94 billion, a price-to-earnings ratio of 26.80, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts predict that Insulet Corporation will post 6.51 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source